Mitochondrial transcription factor A (TFAM) emerges as candidate biomarker for osteoporosis, correlating with bone mineral density
Background
Mitochondrial dysfunction is increasingly recognized as a critical factor in the pathogenesis of osteoporosis, a debilitating bone disease characterized by reduced bone mineral density and increased fracture risk. Current diagnostic methods primarily rely on bone mineral density (BMD) measurements, which often detect the disease at advanced stages. While links between mitochondrial health and bone metabolism are established, the specific roles of key mitochondrial regulators like mitochondrial transcription factor A (TFAM) and the interplay with oxidative stress markers remain underexplored. Understanding these connections could unveil novel diagnostic biomarkers or therapeutic targets, addressing a significant gap in early detection and intervention strategies for osteoporosis.
Study Design
This exploratory cross-sectional study investigated the relationship between TFAM, oxidative stress markers, and osteoporosis. The study enrolled 48 participants aged 50-75, comprising 12 non-osteoporosis patients (control group) and 36 osteoporosis patients. Researchers assessed bone mineral density (BMD) in all participants. Subsequently, serum and bone tissue samples were collected and analyzed for various markers. Specifically, they measured levels of TFAM, RANKL, OPG, BMP, SOD2, and MDA using methods such as protein expression analysis and mRNA quantification. The primary objective was to identify potential associations between these markers and osteoporosis status and BMD.
Results
Analysis revealed no significant differences in baseline characteristics like age, height, weight, or BMI between the osteoporosis and control groups. However, key differences emerged in biochemical markers. The osteoporosis group exhibited significantly higher serum MDA levels (a marker of oxidative stress) and lower serum SOD2 levels (an antioxidant enzyme) compared to the control group. Further, bone tissue analysis in osteoporosis patients showed a notable decrease in both TFAM and OPG expression, alongside a significant increase in RANKL expression. BMP levels did not show a consistent change across protein and mRNA analyses. > Bone mineral density (BMD) was positively correlated with SOD2, TFAM, and OPG (all p < 0.05) and negatively correlated with MDA and RANKL (all p < 0.05). In a multiple regression model, TFAM demonstrated a significant independent association with BMD (β = 0.326, P = 0.005), even though the model was acknowledged to be limited by small sample size and potential overfitting. The area under the receiver operating characteristic curve (AUC) for TFAM as a potential biomarker was 0.706 (95% CI: 0.52-0.86), suggesting moderate discriminatory power for osteoporosis.
Key Findings
- Osteoporosis patients showed higher serum MDA levels and lower SOD2 levels compared to controls.
- Bone tissue of osteoporosis patients had decreased TFAM and
OPGexpression, and increasedRANKLexpression. - Bone mineral density (BMD) positively correlated with TFAM, SOD2, and
OPG. - BMD negatively correlated with MDA and
RANKL. - TFAM showed a significant association with BMD (β = 0.326, P = 0.005), with an AUC of 0.706.
Why It Matters
This study provides initial evidence that TFAM could serve as a novel candidate biomarker for osteoporosis, offering a potential avenue for improved diagnostic strategies. Current osteoporosis diagnosis often relies on BMD, which may not capture early disease progression or the underlying metabolic dysfunction. A circulating or tissue-based biomarker like TFAM, reflecting mitochondrial health and oxidative stress, could enable earlier detection, risk stratification, and potentially guide more personalized interventions. Integrating TFAM assessment into future diagnostic panels could enhance the ability to identify individuals at risk or with early-stage osteoporosis, complementing existing BMD measurements. This could lead to more timely therapeutic interventions, potentially slowing disease progression and reducing fracture incidence. Further research is needed to validate these findings in larger cohorts and explore its utility in monitoring treatment response.